让智能体「规模化」设计新型抗体分子，「寻明生科」获数千万美元A轮融资丨早起看早期

Core Insights - Aureka Biotechnologies has recently completed a multi-million dollar Series A financing round, led by Five Sources Capital and Qiming Venture Partners, with existing investor Neurali Capital increasing its stake [3] - The funds will be used to advance the company's core research pipeline into critical clinical stages and to expand collaborations with global biopharmaceutical companies [3] Group 1: Company Overview - Aureka Biotechnologies focuses on the development of generative antibody drugs, utilizing proprietary platforms for antibody design and molecular innovation [3][4] - The company has achieved commercial revenue in the millions of dollars over the past two years through collaborations with multiple pharmaceutical companies in Europe and the U.S. [5] Group 2: Technology and Innovation - Aureka has developed a data-driven model that integrates autonomous intelligent systems with scientists and high-throughput experimental platforms, significantly enhancing the efficiency of antibody drug development [4][5] - The company has established two high-throughput digital biology methods: one for collecting affinity-related data through yeast evolution and another for functional screening of antibodies using microfluidics [5] Group 3: Market Position and Future Prospects - The ability to create differentiated pipelines and advance them to clinical stages is crucial for biotech companies to gain recognition from investors, as it indicates potential for clear commercial returns [6] - Aureka aims to leverage new technologies to address unmet needs in the metabolic field, potentially leading to significant market value [6]